Santen Oy | MedPath

Phase III Trial Shows Superior Efficacy of Preservative-Free Latanoprost Emulsion for Glaucoma Treatment

3 months ago

• A Phase III trial demonstrated that preservative-free latanoprost eye drop emulsion achieved superior IOP reduction compared to preserved latanoprost, with a significant -0.6 mmHg treatment difference at peak measurement. • The new formulation showed marked improvement in ocular surface disease signs, with greater reduction in corneal fluorescein staining scores compared to preserved latanoprost (p=0.001). • Patient satisfaction was notably higher with the preservative-free formulation (98.4% vs 90.5%), while showing fewer treatment-related adverse events (5.7% vs 10.9%) compared to preserved latanoprost.